blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4197541

EP4197541 - ABIRATERONE ACETATE-CONTAINING COMPOSITION AND APPLICATION THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.05.2025
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  20.06.2024
FormerGrant of patent is intended
Status updated on  16.02.2024
FormerExamination is in progress
Status updated on  01.09.2023
FormerRequest for examination was made
Status updated on  19.05.2023
Most recent event   Tooltip24.10.2025Lapse of the patent in a contracting state
New state(s): IE		published on 26.11.2025  [2025/48]
Applicant(s)For all designated states
Hunan Huize Biopharma S&T Co., Ltd
Building 3, Wanwei Sci&Tech Park
No. 136 Wanglong Road
High-Tech Industrial Development Zone
Changsha, Hunan 410205 / CN
[2023/25]
Inventor(s)01 / YI, Mulin
Changsha, 410205 / CN
 [2023/25]
Representative(s)Zwicker, Jörk
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
[2023/25]
Application number, filing date22212792.012.12.2022
[2023/25]
Priority number, dateCN20211153201715.12.2021         Original published format: CN202111532017
CN2022104944117.01.2022         Original published format: CN202210049441
[2023/25]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP4197541
Date:21.06.2023
Language:EN
[2023/25]
Type: B1 Patent specification 
No.:EP4197541
Date:24.07.2024
Language:EN
[2024/30]
Search report(s)(Supplementary) European search report - dispatched on:EP04.05.2023
ClassificationIPC:A61K31/58, A61P13/08, A61P35/00, A61K9/107, A61K47/10, A61K47/14, A61K9/48, A61K47/44
[2023/25]
CPC:
A61K9/1075 (EP,US); A61K31/58 (EP,US); A61K47/14 (EP,US);
A61K47/44 (EP,US); A61K9/4858 (EP,US); A61P13/08 (EP);
A61P15/00 (US); A61P35/00 (EP,US); A61K47/10 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   ME,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/25]  
TitleGerman:ABIRATERONACETATHALTIGE ZUSAMMENSETZUNG UND ANWENDUNG DAVON[2023/25]
English:ABIRATERONE ACETATE-CONTAINING COMPOSITION AND APPLICATION THEREOF[2023/25]
French:COMPOSITION CONTENANT DE L'ACÉTATE D'ABIRATÉRONE ET SON APPLICATION[2023/25]
Examination procedure12.12.2022Examination requested  [2023/25]
03.07.2023Amendment by applicant (claims and/or description)
03.07.2023Date on which the examining division has become responsible
05.09.2023Despatch of a communication from the examining division (Time limit: M04)
02.11.2023Reply to a communication from the examining division
16.02.2024Communication of intention to grant the patent
12.06.2024Fee for grant paid
12.06.2024Fee for publishing/printing paid
12.06.2024Receipt of the translation of the claim(s)
Opposition(s)25.04.2025No opposition filed within time limit [2025/27]
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCZ24.07.2024
HR24.07.2024
MC24.07.2024
PL24.07.2024
SK24.07.2024
SM24.07.2024
NO24.10.2024
RS24.10.2024
GR25.10.2024
IS24.11.2024
IE12.12.2024
[2025/48]
Former [2025/33]CZ24.07.2024
HR24.07.2024
MC24.07.2024
PL24.07.2024
SK24.07.2024
SM24.07.2024
NO24.10.2024
RS24.10.2024
GR25.10.2024
IS24.11.2024
Former [2025/23]CZ24.07.2024
HR24.07.2024
PL24.07.2024
SK24.07.2024
SM24.07.2024
NO24.10.2024
RS24.10.2024
GR25.10.2024
IS24.11.2024
Former [2025/11]HR24.07.2024
PL24.07.2024
NO24.10.2024
RS24.10.2024
GR25.10.2024
IS24.11.2024
Former [2025/09]PL24.07.2024
NO24.10.2024
GR25.10.2024
IS24.11.2024
Former [2025/08]PL24.07.2024
NO24.10.2024
GR25.10.2024
Documents cited:Search[ID] WO2021057042  (HUNAN HUIZE BIO PHARMACEUTICAL CO LTD et al.)
 [IDP] EP4035657  (HUNAN HUIZE BIO PHARMACEUTICAL CO LTD et al.)
 [ID] WO2014009434  (SANDOZ AG et al.) [ID] 1-6,10,11 * the whole document * * example - * * claim - *
 [IDP] EP3854384  (ADAMED PHARMA S A et al.) [IDP] 1-6,10,11 * the whole document * * example - * * claim - *
 [A] CN105055314  (HANGZHOU ANDE TECHNOLOGY CO LTD et al.) [A] 1-11 * page 1, line 1 - line 6 * * example - * * table 4 * * claim - *
by applicantCN107278152
 WO2021057042
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.